Posadas RC

Language: Spanish
References: 6
Page: 139-141
PDF size: 32.45 Kb.

ABSTRACT

Clinical trials have demonstrated that reduction of low density lipoprotein cholesterol (LDL-C) reduces the incidence of major cardiac events in patients with coronary heart disease (CHD). Recently, two major secondary prevention trials that evaluated the impact of increasing low serum levels of high density lipoprotein cholesterol (HDLC) and decreasing serum triglycerides on cardiovascular morbidity and mortality were published. This paper briefly summarizes the characteristics and results of these two studies. In the veterans Affairs HDL Intervention Study (VA-HIT), LDL-C was not changed; HDL-C increased 6.0% and triglycerides were reduced 31% by gemfibrozil. The lipid changes in the Bezafibrate Infarction Prevention (BIP) study were LDL-C -6.5%, HDL-C 18%; and triglycerides -21%. In VA-HIT, there was a 22% reduction (p= 0.006) in major CHD events, whereas in the BIP study a nonsignificant reduction of only 9.4% was observed. It is not clear why the effectiveness of fibrate therapy was different in the two studies. From these results it has been suggested that for most CHD patients, the 3-hydroxy-3-methylghutaryl coenzyme A reductase inhibitors (statins) will remain the initial drugs of choice, but fibrates may be of use in a subgroup of patients.

REFERENCES

1. AUSTIN MA, HOCKANSON JE, EDWARDS KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81(4A): 7B-12B.

2. RUBINS HB, ROBINS SJ, COLLINS D: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans affairs high-density lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.

3. BODEN WE, PEARSON TA: Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol 2000; 85: 645-650.

4. THE BIP STUDY GROUP: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease, the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27.

5. HAFFNER SM: Secondary prevention of coronary heart disease. The role of fibric acids. Circulation 2000; 102: 2-4.

6. LA ROSA JC: Future cardiovascular and point studies: Where will the research take us? Am J Cardiol 1999; 84: 454-458.